Experimental HCV Drugs
Experimental HCV Drugs
AASLD 2012: Abbott Interferon-free Combination 'Promising' in Harder-to-treat People with Hep C
- Details
- Category: Experimental HCV Drugs
- Published on Tuesday, 13 November 2012 00:00
- Written by Keith Alcorn
Over 79% of previously untreated and null-responder patients with genotype 1a hepatitis C achieved a sustained virological response 12 weeks after completing treatment with an interferon-free combination of 2 or 3 direct-acting antiviral agents developed by Abbott (ABT-450, ABT-267, and/or ABT-333), investigators reported at the American Association for the Stu
dy of Liver Diseases Liver Meeting (AASLD 2012) this week in Boston.
AASLD 2012: High Rate of Response to Daclatasvir and Asunaprevir in Harder-to-treat Hep C Patients
- Details
- Category: Experimental HCV Drugs
- Published on Monday, 12 November 2012 00:00
- Written by Keith Alcorn
Although an interferon-free combination of antiviral drugs developed by Bristol-Myers Squibb (BMS) to treat hepatitis C was highly effective in curing the infection in previous null responders with HCV genotype 1b infection, some new antiviral drugs may still need to be administered with interferon in harder-to-treat patients with genotype 1a, researchers reported at the American Association for the Study of Liver Diseases Liver Meeting (AASLD 2012) in Boston.
Merck Will Soon Start 2 New Trials of MK-5172 in Interferon-free Hepatitis C Regimens
- Details
- Category: HCV Treatment
- Published on Friday, 09 November 2012 00:00
- Written by Press Release
Merck and Co. announced last week that it plans to start 2 new clinical trials to evaluate its investigational hepatitis C virus (HCV) protease inhibitor MK-5172 in all-oral regimens containing ribavirin with or without the company's early-stage NS5A inhibitor MK-8742. Both studies will enroll previously untreated genotype 1 chronic hepatitis C patients.
AASLD 2012: Danoprevir and Mericitabine Work for Prior Non-responders, Hep C Patients with Cirrhosis
- Details
- Category: HCV Treatment
- Published on Monday, 12 November 2012 00:00
- Written by Liz Highleyman
The experimental hepatitis C drugs danoprevir and mericitabine, with or without pegylated interferon and ribavirin, showed good safety and efficacy in previously treated patients, according to findings from the MATTERHORN study presented at the American Association for the Study of Liver Diseases (AASLD) Liver Meeting this week in Boston. Another analysis from the same trial showed good outcomes for people with liver fibrosis.
Vertex Announces Agreements to Develop Interferon-free VX-135 Regimens for Hepatitis C
- Details
- Category: HCV Treatment
- Published on Friday, 02 November 2012 00:00
- Written by Press Release
Vertex Pharmaceuticals this week announced that it has made separate agreements with Janssen Pharmaceuticals and GlaxoSmithKline (GSK) to evaluate all-oral regimens containing its HCV polymerase inhibitor VX-135 (also known as ALS-2200) for previously untreated genotype 1 chronic hepatitis C patients.
More Articles...
- 4-Drug Oral Regimen Cures More than 90% of Chronic Hepatitis C Patients
- Interferon-free HCV Treatment: Simeprevir and ALS-2200 Enter Phase 2 All-oral Studies
- ICAAC 2012: HCV Polymerase Inhibitor Sofosbuvir Appears Safe and Effective for HIV/HCV Coinfected People
- Monoclonal Antibody May Help Prevent and Clear Hepatitis C Virus
Web Design and Development by